Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
财务表现 - Bristol-Myers Squibb Company (BMY)报告的调整后每股亏损为4.40美元,比Zacks Consensus Estimate的每股亏损4.53美元要窄[1] - 总收入为119亿美元,超过了Zacks Consensus Estimate的114亿美元[3] - 美国收入增长7%,达到85亿美元,主要受益于Eliquis、Reblozyl和Opdualag的销售增长[4]